Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 2Glioma 2Glioblastoma 2Cholangiocarcinoma 2Spinal Cord Neoplasms 1Oligodendroglioma 1Neoplasms 1Myelodysplastic Syndromes 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Bile Duct Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 4Flucytosine 4vocimagene amiretrorepvec 3vorasidenib 2trametinib 2paclitaxel-Angiopep-2 conjugate 2dabrafenib 2Surgical Procedures, Operative 2OKN 007 2Chlorotoxin 2Carmustine 2talampanel 1selinexor 1pemigatinib 1pembrolizumab 1olutasidenib 1motexafin gadolinium 1exatecan 1Vincristine 1Radiation 1PF-06840003 1ONC206 1O(6)-benzylguanine 1Metabolism 1IL13-PE38 1Genetic Therapy 1Genetic Engineering 1Filgrastim 1Fentanyl 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Oligodendroglioma × olutasidenib × Clear all
NCT06161974 2025-02-21

Study of Olutasidenib and Temozolomide in HGG

Rigel Pharmaceuticals

Phase 2 Recruiting
60 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡